CORRESPONDENCE

Vaccine against swine influenza F E André, MRCPATH, and others.....1527	Laparoscopy explosion hazards with nitrous oxide G B Drummond, FFARCS, and D B Scott, FFARCS.....1531	Occult abdominal injury B J Pardy, FRCS.....1534
Multiple sclerosis among immigrants J F Kurtzke, FACP.....1527	Prevention of coronary heart disease M A Crawford, PHD; José A Day, MB....1532	Myelotoxicity of gold P R V Tomson, FRCGP; April G L Kay, MB.....1534
Folate-responsive neuropathy M C Bateson, MRCP; J Runcie, FRCPGLAS, and M Manzoor, MB.....1528	Fluid therapy in malaria V Sitprijia, FACP.....1532	Status of medical laboratory scientists A D Farr, FIMLS.....1534
Vaginal candidosis G R Daniel, MB; R A Sparks, MRCP; C S Good, FRCS; R Pumpianski, MD, and S Ganor, MD.....1528	Unexplained hepatitis following halothane W K Slack, DA.....1532	Doctors and administrators R J Luck, FRCS, and others.....1534
Fetal activity and fetal wellbeing P R B Pedlow, FRCOG; D D Mathews, MRCOG.....1529	Five separate malignancies in one patient P A Jones, FRCS.....1533	Ophthalmic medical practitioners W J C C Rich, FRCS.....1535
Febrile fits S Livingston, MD, and Lydia L Pauli, MD..1530	Hazards of monocomponent insulins C M Kesson, MRCP.....1533	Campaign for Independence in Medicine J R Saunders, FRCOG.....1535
Perhexiline maleate in angina pectoris J D F Lockhart, MB, and H C Masheter, MB 1530	Computer-held medical records C J Bulpitt, MRCP, and others.....1533	Points from letters Inlet or outlet? (D I Grieve); Intermittent claudication (T Chakera); Visual fields in coma? (D W W Bullimore); Nostalgia: a vanished disease (J H S Pettit); Impact therapy for chronic bronchitis (J B Tracey); Flupenthixol (N P Mann); Ocular complications of ethambutol (R S Bartholomew); Profession and Government (P R J Vickers) 1535
Intermittent claudication M Thomas, FRCS, and C R G Quick, FRCS..1531	Incidence of dermatographism R F Q Johnson, PHD.....1533	
	Cigarette consumption M Daube.....1534	

Correspondents are urged to write briefly so that readers may be offered as wide a selection of letters as possible. So many are being received that the omission of some is inevitable. Letters should be signed personally by all their authors.

Vaccine against swine influenza

SIR,—WHO influenza experts have recently recommended the inclusion of the A/New Jersey/8/76 (Hsw₁N₁) virus in inactivated vaccines for 1976-7.¹ That decision was prompted by the small outbreak caused by this strain in a military training camp in the USA which led President Ford to advocate a Government-sponsored mass immunisation campaign. This unprecedented measure was dictated by the current low level of specific immunity of most people younger than 50 against this virus, which is antigenically related to the swine influenza virus thought to have been responsible for the catastrophic 1918 pandemic (Spanish "flu").

We produced in our laboratories a small lot of β -propiolactone-inactivated whole-virion vaccine containing 400 IU of A/New Jersey/8/76 (X-53 (Hsw₁N₁), 400 IU of A/Victoria/3/75 (X-47 (H₂N₂), and 360 IU of B/Hong Kong/8/73 per dose in order to vaccinate company employees who are, or

could become, engaged in influenza vaccine research, production, and control. The opportunity was taken to investigate the serological response to one dose of this new vaccine.

Blood samples were obtained about one month before and 19 days after vaccination from a total of 40 vaccinees (14 women (19-57 years) and 26 men (22-57 years)). Only four had not previously received influenza vaccine. Antibody titrations are still in progress but we should like to report our findings on the serum haemagglutination inhibition (HI) antibody response to the A/New Jersey/8/76 component in the vaccine. To our knowledge these are the first to become available. Each HI titre is the geometric mean of two independent titrations by a standard technique using cholera filtrate-treated serum and 3 haemagglutinating units of A/New Jersey antigen. The results are summarised in the table.

	Age range of vaccinees		
	19-44 years (n = 25)	≥45 years (n = 15)	All ages (n = 40)
Vaccinees with HI titre ≤40	25 (100%)	7 (47%)	32 (80%)
Geometric mean HI titre and range ..	5 (20%)	2 (13%)	7 (18%)
Geometric mean rise in titre	14 (≤13*21)	45 (≤13-229)	21 (≤13-229)
Arithmetic mean rise in titre	110 (18-1293)	160 (≤13-1087)	127 (≤13-1293)
Vaccinees showing ≥4-fold rise in titre ..	19 (76%)	7 (47%)	26 (65%)

*An undetectable antibody HI titre (≤13) was assigned a value of 13 for calculations.

It is clear that 400 IU of A/New Jersey/8/76 vaccine gave a good homologous serum HI antibody response after a single dose in vaccinees above 45 years, 11 of whom had pre-existing antibodies to the strain owing to the fact that swine-like viruses circulated among humans up to about the early 1930s. The response was equally good, if not better, in younger vaccinees who are unlikely to have been exposed to swine-influenza viruses. Three of these had low prevaccination titres and we suspect that these reflect cross-reacting antibodies. Of 26 vaccinees with undetectable HI titre (≤13) before vaccination, 20 reached a titre of ≥40 after vaccination. Only one person showed no rise in serum HI titre against A/New Jersey after vaccination. Thus we conclude that this dose of vaccine will probably confer adequate immunity against the A/New Jersey virus, at least to all adult age groups.

F ANDRÉ
J W LEYENHORST
J C SEKET
D ZELLENRATH

Philips-Duphar BV,
Weesp, Holland

¹ World Health Organisation, *Weekly Epidemiological Record*, 1976, 51, No 6.

Multiple sclerosis among immigrants

SIR,—Once again I must disagree with my good friend, Dr Geoffrey Dean. In their admirable study on multiple sclerosis (MS) among immigrants in greater London (10 April, p 861) Dr Dean and his colleagues conclude that "those who migrate from low-risk countries to London, a high-risk area, keep their low risk of developing the disease;